Concepedia

Kenneth Algazy

KA

Statistics

Publications

13

Citations

363

H-Index

13

Active since

1972

Affiliations

University of Pennsylvania(Current)

California University of Pennsylvania

University of Pennsylvania Health System

Fox Chase Cancer Center

Kenneth Algazy is an author at University of Pennsylvania specializing in medicine, oncology, and chemotherapy.

Publications per year

1972–2013

13

Publications

13

A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer

David I. Rosenthal, Sue S. Yom, Li Liu et al. · Investigational New Drugs · 2002 · 48 citations

Medicine, Oncology, Radiation Oncology +12

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

James Stevenson, Weijing Sun, Maryann Gallagher et al. · PubMed · 2002 · 44 citations

Medicine, Pharmacology, Pharmacotherapy +13

Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer

James Stevenson, Maryann Redlinger, Leo A. J. Kluijtmans et al. · Journal of Clinical Oncology · 2001 · 43 citations

Medicine, Oncology, Pharmacology +17

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m<sup>2</sup>for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury, Eric J. Sherman, Donna Lisa et al. · Journal of the National Comprehensive Cancer Network · 2012 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

James Stevenson, Chu Won Nho, Steven W. Johnson et al. · Journal of Clinical Oncology · 2004 · 31 citations

Medicine, Oncology, Pharmacology +14

1–5 of 13